Shares of Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shot up 7.8% during trading on Wednesday . The stock traded as high as $0.20 and last traded at $0.19. 19,100 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The business’s 50-day moving average is $0.19 and its 200 day moving average is $0.19.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Featured Articles
- Five stocks we like better than Vyant Bio
- Ride Out The Recession With These Dividend Kings
- Is This Telehealth Stock a Buy After the Recent Pullback?
- Learn Technical Analysis Skills to Master the Stock Market
- Safeguard Against Credit Card Risks with This Top Financial Stock
- Most active stocks: Dollar volume vs share volume
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
